<p>Cullinan Therapeutics Inc. will host an in-person event for analysts and institutional investors on December 8, 2025, during the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, FL. The event will follow an oral presentation of results from the Phase 1 study of CLN-049 in patients with AML or MDS earlier that morning. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572329-en) on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CGEM

<p>Cullinan Therapeutics Inc. will host an in-person event for analysts and institutional investors on December 8, 2025, during the ASH Annual Meeting in Orlando, FL. This event will follow an oral presentation of Phase 1 study results of CLN-049 in AML or MDS patients earlier that morning.</p>

Cullinan Therapeutics to Host Analyst and Investor Event at ASH Annual Meeting